Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Researchers Characterize PrimPol, a Novel Human DNA Polymerase

By BiotechDaily International staff writers
Posted on 19 Nov 2013
PrimPol, a novel enzyme cloned in human cells, has been shown to initiate DNA chains with deoxynucleotides unlike regular primases, which exclusively use ribonucleotides.

Investigators at the biotechnology company SYGNIS AG (Madrid, Spain; and Heidelberg, Germany) in collaboration with researchers at the Spanish National Research Council (Madrid) recently isolated and characterized PrimPol.

They reported in the October 24, 2013, online edition of the journal Molecular Cell that PrimPol functioned as both DNA primase and DNA polymerase, and demonstrated high tolerance to damaged DNA. The primase function of PrimPol allowed it to begin reading and copying DNA without the need for random ribonucleotide primers, as required by all other commercially available polymerases. The use of random primers can bias sequencing and amplification results. The polymerase function of PrimPol displayed high specific activity, being extremely efficient when copying DNA strands with different lesions, such as abasic sites or 8-oxoguanine.

Subcellular fractionation and immunodetection studies showed that PrimPol could be found in both nuclear and mitochondrial DNA compartments. Its activity was detectable in mitochondrial lysates from human and mouse cells but was absent from mitochondria derived from mice that had been genetically engineered to lack the PRIMPOL gene. PRIMPOL gene silencing or ablation in human and mouse cells impaired mitochondrial DNA replication.

Senior author Dr. Luis Blanco, research professor at the Spanish National Research Council, said, "I am convinced that this fantastic enzyme will open numerous novel applications in the field of molecular biology, some of them we can only hint at this moment given the highly innovative potential of its key features."

SYGNIS AG is currently developing a new thermostable version of the enzyme that is expected to make an important contribution to the DNA amplification and sequencing field.

Related Links:

SYGNIS AG 
Spanish National Research Council



WATERS CORPORATION

Channels

Drug Discovery

view channel
Image: Molecular model of the anti-cancer drug 5-fluorouracil (Photo courtesy of Wikimedia Commons).

Novel Microcapsule Approach Reduces Toxic Side Effects of Chemotherapy

Cancer researchers have reduced chemotherapy's toxic side effects by using nanoporous capsules to transport an enzyme to the site of a tumor where it is activated by a selective heating process to convert... Read more

Lab Technologies

view channel
Image: The gene assembly robot, the GeneTheatre (Photo courtesy of Analytik Jena AG).

Genomic Research Laboratories Await New Compact Liquid Handling System

A small footprint benchtop liquid handler that automates multiple gene assembly tasks and associated procedures such as PCR setup is now available for use by biotech and genomic research laboratories.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.